Expression and clinical significance of the nin one binding protein and p38 MAPK in prostate carcinoma

International Journal of Clinical and Experimental Pathology

Volumn 6, Issue 11, 2013, Pages 2300-2311

  Che, Jian Ping ^a   Li, Wei ^a   Yan, Yang ^a   Liu, Min ^a   Wang, Guang Chun ^a   Li, Qian Yu ^a   Yang, Bin ^b   Yao, Xu Dong ^a   Zheng, Jun Hua ^a  

^a TONGJI UNIVERSITY   (China)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Histopathologic grade; NOB1; P38 MAPK; Prognostic markers; Prostate carcinoma

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE P38; NOB1 PROTEIN, HUMAN; NUCLEAR PROTEIN; RNA BINDING PROTEIN; TUMOR MARKER;

AGED; ARTICLE; CARCINOMA; DISEASE COURSE; ENZYMOLOGY; GENETIC TRANSFECTION; GENETICS; HEK293 CELL LINE; HISTOPATHOLOGIC GRADE; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MALE; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; NOB1; P38 MAPK; PATHOLOGY; PROGNOSTIC MARKERS; PROSTATE CARCINOMA; PROSTATE TUMOR; PROSTATECTOMY; RETROSPECTIVE STUDY; RNA INTERFERENCE; TIME; TREATMENT OUTCOME; TUMOR CELL LINE; TUMOR RECURRENCE;

HISTOPATHOLOGIC GRADE; NOB1; P38 MAPK; PROGNOSTIC MARKERS; PROSTATE CARCINOMA;

AGED; CARCINOMA; CELL LINE, TUMOR; DISEASE PROGRESSION; HEK293 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NUCLEAR PROTEINS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RNA INTERFERENCE; RNA-BINDING PROTEINS; TIME FACTORS; TRANSFECTION; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84887120253     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Siegel R, Naishadham D and Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2. Ferlay J, Parkin DM and Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010;46:765-781.
3. Klotz L. Re:editorial comment on focal therapy for localised unifocal and multifocal prostate cancer:a prospective development study (lancet oncol 2012;13:622-632). J Urol 2013;189:1601-1602.
4. Catalona WJ, D'Amico AV, Fitzgibbons WF, Kosoko-Lasaki O, Leslie SW, Lynch HT, Moul JW, Rendell MS and Walsh PC. What the U.S. Preventive Services Task Force missed in its prostate cancer screening recommendation. Ann Intern Med 2012;157:137-138.
5. Moyer VA;U.S. Preventive Services Task Force. Screening for prostate cancer:U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012;157:120-134.
6. Dhillon AS, Hagan S, Rath O and Kolch W. MAP kinase signalling pathways in cancer. Oncogene 2007;26:3279-3290.
7. Chang L and Karin M. Mammalian MAP kinase signalling cascades. Nature 2001;410:37-40.
8. Appella E and Anderson CW. Post-translational modifications and activation of p53 by genotoxic stresses. Eur J Biochem 2001;268:2764-2772.
9. Chung LY, Tang SJ, Sun GH, Chou TY, Yeh TS, Yu SL and Sun KH. Galectin-1 promotes lung cancer progression and chemoresistance by upregulating p38 MAPK, ERK, and cyclooxygenase-2. Clin Cancer Res 2012;18:4037-4047.
10. Li XD, Liu ZY, Chang B, Liu DX, Chen B, Guo C, Wang YG, Xu JK, Huang DY and Du SX. Panax notoginseng saponins promote osteogenic differentiation of bone marrow stromal cells through the ERK and P38 MAPK signaling pathways. Cell Physiol Biochem 2011;28:367-376.
11. Jagielska J, Kapopara PR, Salguero G, Scherr M, Schutt H, Grote K, Schieffer B and Bavendiek U. Interleukin-1 assembles a proangiogenic signaling module consisting of caveolin-1, tumor necrosis factor receptor-associated factor 6, p38-mitogen-activated protein kinase (MAPK), and MAPK-activated protein kinase 2 in endothelial cells. Arterioscler Thromb Vasc Biol 2012;32:1280-1288.
12. Zhang Y, Ni J, Zhou G, Yuan J, Ren W, Shan Y, Tang W, Yu L and Zhao S. Cloning, expression and characterization of the human NOB1 gene. Mol Biol Rep 2005;32:185-189.
13. Veith T, Martin R, Wurm JP, Weis BL, Duchardt-Ferner E, Safferthal C, Hennig R, Mirus O, Bohnsack MT, Wohnert J and Schleiff E. Structural and functional analysis of the archaeal endonuclease Nob1. Nucleic Acids Res 2012;40:3259-3274.
14. Zhou J, Xu T, Yan Y, Qin R, Wang H, Zhang X, Huang Y, Wang Y, Lu Y, Fu D and Chen J. MicroRNA-326 Functions as a Tumor Suppressor in Glioma by Targeting the Nin One Binding Protein (NOB1). PLoS One 2013;8:e68469.
15. Lee MT, Ouyang B, Ho SM and Leung YK. Differential expression of estrogen receptor beta isoforms in prostate cancer through interplay between transcriptional and translational regulation. Mol Cell Endocrinol 2013;376:125-135.
16. Siegel R, Naishadham D and Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
17. Choy B, Gordetsky J and Miyamoto H. Clinicopathologic features of prostate cancer in patients diagnosed by age 45 who underwent radical prostatectomy. Eur Urol 2012;62:354-355.
18. van Vugt HA, Roobol MJ, van der Poel HG, van Muilekom EH, Busstra M, Kil P, Oomens EH, Leliveld A, Bangma CH, Korfage I and Steyerberg EW. Selecting men diagnosed with prostate cancer for active surveillance using a risk calculator:a prospective impact study. BJU Int 2012;110:180-187.
19. Rajpar S and Fizazi K. Bone targeted therapies in metastatic castration-resistant prostate cancer. Cancer J 2013;19:66-70.
20. Khatri A and Russell PJ. Targeted, gene-directed enzyme prodrug therapies to tackle diversity and aggression of late stage prostate cancer. Discov Med 2007;7:39-45.
21. Lin Y, Peng S, Yu H, Teng H and Cui M. RNAi-mediated downregulation of NOB1 suppresses the growth and colony-formation ability of human ovarian cancer cells. Med Oncol 2012;29:311-317.
22. Pertschy B, Schneider C, Gnadig M, Schafer T, Tollervey D and Hurt E. RNA helicase Prp43 and its co-factor Pfa1 promote 20 to 18 S rRNA processing catalyzed by the endonuclease Nob1. J Biol Chem 2009;284:35079-35091.
23. Turjanski AG, Vaque JP and Gutkind JS. MAP kinases and the control of nuclear events. Oncogene 2007;26:3240-3253.
24. Wagner EF and Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 2009;9:537-549.
25. Sharma GD, He J and Bazan HE. p38 and ERK1/2 coordinate cellular migration and proliferation in epithelial wound healing:evidence of cross-talk activation between MAP kinase cascades. J Biol Chem 2003;278:21989-21997.
26. Bode AM and Dong Z. The functional contrariety of JNK. Mol Carcinog 2007;46:591-598.
27. Faust D, Schmitt C, Oesch F, Oesch-Bartlomowicz B, Schreck I, Weiss C and Dietrich C. Differential p38-dependent signalling in response to cellular stress and mitogenic stimulation in fibroblasts. Cell Commun Signal 2012;10:6.
28. Sun B, Zhang X, Yonz C and Cummings BS. Inhibition of calcium-independent phospholipase A2 activates p38 MAPK signaling pathways during cytostasis in prostate cancer cells. Biochem Pharmacol 2010;79:1727-1735.